Crestor (rosuvastatin calcium) from AstraZeneca has received a new indication as an adjunct to diet to slow the progression of atherosclerosis in adult patients with elevated cholesterol, differentiating it from competitors in the cholesterol-lowering marketplace.


Its other indications are as adjunctive therapy to diet to reduce cholesterol levels in patients with primary hyperlipidemia or mixed dyslipidemia. AstraZeneca’s submission to the FDA was based largely on the results of a study called METEOR (Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin) which demonstrated a slowing of progression of atherosclerosis in patients with early signs of the disease, elevated LDL cholesterol, and low cardiovascular risk, taking Crestor 40 mg.

Continue Reading